BidaskClub upgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a strong-buy rating in a research note released on Thursday morning.

A number of other research firms have also recently issued reports on MRNS. Cantor Fitzgerald reaffirmed a buy rating and issued a $19.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, August 2nd. Mizuho reaffirmed a buy rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, August 2nd. Robert W. Baird initiated coverage on shares of Marinus Pharmaceuticals in a report on Wednesday, May 23rd. They issued an outperform rating and a $15.00 price target for the company. ValuEngine raised shares of Marinus Pharmaceuticals from a hold rating to a buy rating in a report on Saturday, June 2nd. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Marinus Pharmaceuticals in a report on Wednesday, June 6th. They issued a buy rating and a $20.00 price target for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Marinus Pharmaceuticals has a consensus rating of Buy and a consensus price target of $19.67.

NASDAQ MRNS opened at $8.78 on Thursday. The firm has a market capitalization of $355.81 million, a price-to-earnings ratio of -10.98 and a beta of 2.59. Marinus Pharmaceuticals has a 12-month low of $3.31 and a 12-month high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.09). sell-side analysts expect that Marinus Pharmaceuticals will post -0.73 EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. Trexquant Investment LP acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $102,000. GSA Capital Partners LLP acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $141,000. Jennison Associates LLC increased its stake in shares of Marinus Pharmaceuticals by 0.8% in the second quarter. Jennison Associates LLC now owns 2,757,356 shares of the biopharmaceutical company’s stock worth $19,495,000 after acquiring an additional 21,733 shares during the period. Rhumbline Advisers acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $245,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $363,000. Hedge funds and other institutional investors own 63.64% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.

Featured Story: How Buying a Call Option Works

Analyst Recommendations for Marinus Pharmaceuticals (NASDAQ:MRNS)

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.